BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 27, 2007
View Archived Issues
Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs
Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today)
Read More
Exelixis Moving Forward On XL647 After GSK Declines
Read More
ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes
Read More
Aspreva Restructures, Plans To Look Beyond CellCept
Read More
Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth
Read More
Other News To Note
Read More
Clinic Roundup
Read More